

# Mycoplasma Testing Market Set to Surge to \$2.2 Billion by 2032 at a 11.7% CAGR

*In 2022, the mycoplasma testing market was valued at \$0.7 billion and is projected to reach \$2.2 billion by 2032, exhibiting a CAGR of 11.7% from 2023 to 2032.*

WILMINGTON, DE, UNITED STATES, January 31, 2025 /EINPresswire.com/ -- The global [mycoplasma testing market](#) has witnessed significant growth in recent years, reflecting its critical role in ensuring the purity and reliability of biological products. In 2022, the mycoplasma testing market was valued at \$0.7 billion and is projected to reach \$2.2 billion by 2032, exhibiting a CAGR of 11.7% from 2023 to 2032.



The image shows the cover of a research report titled "MYCOPLASMA TESTING MARKET OPPORTUNITIES AND FORECAST, 2023-2032". The cover features a photograph of a scientist in a lab coat and safety glasses working in a laboratory. Text on the cover includes: "Mycoplasma testing market is expected to reach **\$2.2 Billion** in 2032", "Growing at a **CAGR of 11.7%** (2023-2032)", and "Report Code: A11266, www.alliedmarketresearch.com".

## Mycoplasma Testing Market Research Report

Get Sample PDF Copy Here: <https://www.alliedmarketresearch.com/request-sample/A11266>

### Mycoplasma Testing Market Growth Factors

Several key factors are driving the expansion of the mycoplasma testing market:

- 1. Rising Mycoplasma Contamination:** The pharmaceutical and biotechnology industries have experienced an increase in mycoplasma contaminations, necessitating rigorous testing protocols to maintain product integrity.
- 2. Expansion of the Biopharmaceutical Sector:** The growing biopharmaceutical industry demands stringent quality control measures, including mycoplasma testing, to ensure the safety and efficacy of products.
- 3. Regulatory Mandates:** Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established guidelines requiring mycoplasma testing for

biologics and vaccines, further propelling market growth.

4. Technological Advancements: Innovations in diagnostic technologies have led to the development of faster and more accurate mycoplasma testing methods, enhancing the efficiency of detection processes.

## Mycoplasma Testing Market Segmentation

The mycoplasma testing market is segmented based on product type, technology, application, and end user.

### 1. By Product Type:

- Instruments: Devices used for the detection and analysis of mycoplasma in various samples.
- Kits and Reagents: Consumables essential for conducting mycoplasma tests.
- Services: Outsourced testing services provided by specialized laboratories.

### 2. By Technology:

- Polymerase Chain Reaction (PCR): A molecular technique that amplifies DNA sequences, allowing for the rapid and accurate detection of mycoplasma.
- Enzyme-Linked Immunosorbent Assay (ELISA): A plate-based assay technique designed for detecting and quantifying soluble substances such as proteins, antibodies, and hormones.
- Microbial Culture Techniques: Traditional methods involving the cultivation of mycoplasma organisms to detect contamination.
- Enzymatic Methods: Techniques that utilize enzymes to identify mycoplasma presence.

### 3. By Application:

- Cell Line Testing: Ensuring that cell cultures used in research and production are free from mycoplasma contamination.
- Virus Testing: Detecting mycoplasma in viral preparations to ensure the purity of viral vaccines and therapies.
- End-Of-Production Cell Testing: Testing cells at the end of the production process to confirm the absence of mycoplasma contamination.

### 4. By End User:

- Pharmaceutical and Biotechnology Companies: Organizations involved in the development and production of drugs and biological products.
- Academic Research Institutes: Educational institutions conducting research that requires mycoplasma-free cell cultures.
- Cell Banks: Facilities that store cell lines and require regular mycoplasma testing to maintain cell line integrity.
- Contract Research Organizations (CROs): Companies that provide outsourced research services, including mycoplasma testing, to the pharmaceutical and biotechnology industries.

Have Any Query? Ask Our Experts: <https://www.alliedmarketresearch.com/purchase-enquiry/A11266>

## Key Players in the Mycoplasma Testing Market

The mycoplasma testing market features several prominent companies that contribute significantly to its growth. These key players include:

- Thermo Fisher Scientific Inc.
- Charles River Laboratories
- Lonza
- F. Hoffmann-La Roche Ltd.
- Bio-Rad Laboratories, Inc.
- Eurofins Scientific

These companies are at the forefront of developing innovative mycoplasma testing solutions and services, thereby enhancing the overall market landscape.

## Regional Insights

Geographically, the mycoplasma testing market is analyzed across North America, Europe, Asia-Pacific, and LAMEA (Latin America, Middle East, and Africa).

- North America: In 2022, North America accounted for a major share of the mycoplasma testing market and is expected to maintain its dominance during the forecast period. The presence of several major players and advancements in mycoplasma testing technology in the region drive the growth of the market.
- Europe: Europe holds a significant share in the market, attributed to stringent regulatory guidelines and a robust biopharmaceutical industry that necessitates rigorous mycoplasma testing protocols.
- Asia-Pacific: This region is anticipated to exhibit the highest CAGR during the forecast period, driven by the development of healthcare facilities, increase in research activities, and rise in public-private investments in the healthcare sector.
- LAMEA: The LAMEA region is expected to witness steady growth due to improving healthcare infrastructure and increasing awareness about the importance of mycoplasma testing in biological research and production.

The future of the mycoplasma testing market looks promising, with sustained growth driven by technological innovations, regulatory compliance, and increasing awareness about contamination risks. The ongoing expansion of the biopharmaceutical sector, coupled with a heightened focus on quality assurance, will continue to propel the demand for mycoplasma testing worldwide.

Furthermore, emerging markets in Asia-Pacific and Latin America present lucrative opportunities for market players looking to expand their footprint. Companies investing in R&D and strategic partnerships will be well-positioned to capitalize on the growing demand for efficient and reliable mycoplasma testing solutions.

Procure Complete Report Here: [https://www.alliedmarketresearch.com/checkout-final/0b06366e228a0d8d2ec7dd4249236a16?utm\\_source=Nilesh.Musale](https://www.alliedmarketresearch.com/checkout-final/0b06366e228a0d8d2ec7dd4249236a16?utm_source=Nilesh.Musale)

Thanks for reading this article; you can also get an individual chapter-wise sections or region-wise report versions like North America, LATAM, Europe, or Southeast Asia.

#### About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa  
Allied Market Research  
+ + 1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[YouTube](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/782140014>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.